{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:10:24Z","timestamp":1795173024115,"version":"4.10.3"},"reference-count":100,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T00:00:00Z","timestamp":1337212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p>Dipeptidyl peptidase\u20104 (DPP\u20104) inhibitors are oral antidiabetic agents that hold the potential of slowing the progress of type 2 diabetes mellitus. Their long\u2010term safety is still a subject of debate. A systematic review of randomized, controlled trials was undertaken to comprehensively profile the safety of chronic treatment of type 2 diabetes mellitus with DPP\u20104 inhibitors. We searched data sources including MEDLINE, CENTRAL, publishers' and manufacturers' databases. Eligible trials were double\u2010blind, randomized, placebo or active\u2010controlled trials with \u226518 weeks duration in patients with type 2 diabetes reporting safety outcomes. Meta\u2010analysis was performed separately for trials in which the control group received placebo (44 studies), another gliptin (3 studies) and any other antidiabetic drug (20 studies). Risk ratios with 95% confidence intervals were computed using a Mantel\u2010Haenszel fixed\u2010effect model for general safety outcomes, hypoglycaemia and adverse events by system organ class. Of 307 publications retrieved, 67 randomized, controlled trials met the eligibility criteria and were included in this review (4 alogliptin, 8 linagliptin, 8 saxagliptin, 20 sitagliptin, and 27 vildagliptin trials). Adverse events with gliptin treatment were at placebo level (relative risk (RR) 1.02 [0.99, 1.04]). No increased risk of infections was detectable (RR 0.98 [0.93, 1.05] compared to placebo and 1.02 [0.97, 1.07] compared to other antidiabetic drugs). Asthenia (RR 1.57 [1.09, 2.27]) as well as cardiac (RR 1.37 [1.00, 1.89]) and vascular disorders (RR 1.74 [1.05, 2.86] for linagliptin) emerged as adverse events associated with DPP\u20104 inhibitor treatment. The risk of hypoglycaemia was low with DPP\u20104 inhibitor treatment (RR 0.92 [0.74, 1.15] compared to placebo, RR 0.20 [0.17, 0.24] compared to sulphonylureas) in the absence of sulphonylurea or insulin co\u2010therapy, but significantly elevated for combination therapy of sulphonylurea or insulin with sitagliptin or linagliptin (RR 1.86 [1.46, 2.37] compared to placebo). A large body of data supports the long\u2010term safety of gliptin treatment and refutes an increased risk of infections. Further research is needed to clarify a possible link to asthenia, cardiac and vascular events. For combination therapy with insulin or insulin secretagogues, a careful choice of the agent used may limit the risk of hypoglycaemia.<\/jats:p>","DOI":"10.1111\/j.1463-1326.2012.01610.x","type":"journal-article","created":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T12:14:22Z","timestamp":1334924062000},"page":"1061-1072","source":"Crossref","is-referenced-by-count":120,"title":["Longer term safety of dipeptidyl peptidase\u20104 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"14","author":[{"given":"K.","family":"Goo\u00dfen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gr\u00e4ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.19.2088"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.03.002"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.04.015"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2167-8"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","unstructured":"van GenugtenRE van RaalteDH DiamantM.Dipeptidyl peptidase\u20104 inhibitors and preservation of pancreatic islet\u2010cell function: a critical appraisal of the evidenceDiabetes Obes Metab2012;14:101\u2013111.","DOI":"10.1111\/j.1463-1326.2011.01473.x"},{"key":"e_1_2_7_8_2","first-page":"e35","article-title":"Second\u2010line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed\u2010treatment comparison meta\u2010analysis","volume":"5","author":"McIntosh B","year":"2011","journal-title":"Open Med"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.2.194"},{"key":"e_1_2_7_10_2","first-page":"CD006739","article-title":"Dipeptidyl peptidase\u20104 (DPP\u20104) inhibitors for type 2 diabetes mellitus","volume":"2","author":"Richter B","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2009.03.015"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000314690"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.405"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-10-7"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02382.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S16925"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01215.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01214.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0482"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902820519"},{"key":"e_1_2_7_21_2","article-title":"The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database","author":"Raschi E","year":"2011","journal-title":"Acta Diabetol"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02382.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1755"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.77a.09167"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0599"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_7_27_2","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.1.1. Copenhagen: The Nordic Cochrane Centre The Cochrane Collaboration 2011."},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2528"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010035"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1114"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01933.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903156111"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.01016.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01124.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01350.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01391.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03387.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01326.x"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/1479164111404574"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1984"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02510.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/1479164111404575"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02812.x"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01385.x"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903178735"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01334.x"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0703"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01187.x"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.568059"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00914.x"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0706"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00744.x"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.10.009"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01416.x"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02749.x"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60307-8"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0416-z"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X260925"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.10.007"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00839.x"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02353.x"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01173.x"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01204.x"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02589.x"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.12.2874"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.01023.x"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1732"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01040.x"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-970422"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.02938.x"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1234042"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0633-0"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00684.x"},{"key":"e_1_2_7_76_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00859.x"},{"key":"e_1_2_7_77_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1082334"},{"key":"e_1_2_7_78_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1104604"},{"key":"e_1_2_7_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01467.x"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01233.x"},{"key":"e_1_2_7_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02391.x"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2006.12.009"},{"key":"e_1_2_7_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00698.x"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.01021.x"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00875.x"},{"key":"e_1_2_7_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01051.x"},{"key":"e_1_2_7_87_2","doi-asserted-by":"crossref","unstructured":"VollmerM AbletshauserC PennartzC MeierJJ.Wirksamkeit und Sicherheit der fr\u00fchen Kombination von Vildagliptin mit Metformin im Vergleich zu Placebo bei Patienten mit Typ 2 Diabetes.Diabetologie und Stoffwechsel2009;S1:S83.","DOI":"10.1055\/s-0029-1222043"},{"key":"e_1_2_7_88_2","unstructured":"Food and Drug Administration. Label approved on 14\/04\/2011 for Januvia NDA no. 021995 retrieved from US.Available from URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021995s017lbl.pdf. Accessed 10 November 2011."},{"key":"e_1_2_7_89_2","unstructured":"Food and Drug Administration. Label approved on 18\/02\/2011 for Onglyza NDA no. 022350 retrieved from US.Available from URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022350s001s002lbl.pdf. Accessed 10 November 2011."},{"key":"e_1_2_7_90_2","unstructured":"Food and Drug Administration. Label approved on 02\/05\/2011 for Tradjenta NDA no. 201280 retrieved from US.Available from URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/201280lbl.pdf. Accessed 10 November 2011."},{"key":"e_1_2_7_91_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02341.x"},{"key":"e_1_2_7_92_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X261069"},{"key":"e_1_2_7_93_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1771"},{"key":"e_1_2_7_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.885"},{"key":"e_1_2_7_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/002215540205000903"},{"key":"e_1_2_7_96_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0939fje"},{"key":"e_1_2_7_97_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.05.2138"},{"key":"e_1_2_7_98_2","doi-asserted-by":"crossref","unstructured":"JohansenOE NeubacherD von EynattenM PatelS WoerleHJ.Cardiovascular risk with linagliptin in patients with type 2 diabetes: a pre\u2010specified prospective and adjudicated meta\u2010analysis from a large phase III program. 71st American Diabetes Association Scientific Sessions Poster 30\u2010LB. Available from URL:http:\/\/www.diabetesincontrol.com\/articles\/91\u2010how\u2010glp\u20101\u2010works\/11143\u2010ada\u2010five\u2010late\u2010breaking\u2010glp\u20101\u2010abstracts. Accessed 11 November 2011.","DOI":"10.1186\/1475-2840-11-3"},{"key":"e_1_2_7_99_2","unstructured":"Galvus (vildagliptin) European Public Assessment report 17\/09\/2009 (last updated 11\/04\/2011).Available from URL:http:\/\/www.ema.europa.eu. Accessed 15 November 2011."},{"key":"e_1_2_7_100_2","unstructured":"Glimepiride (Amaryl\u00ae) was associated with a somewhat elevated rate of asthenia compared to placebo (1.6% vs. 1%): US Food and Drug Administration. Label approved on 04\/06\/2009 for Amaryl NDA no. 020496.Available from URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020496s021lbl.pdf. Accessed 15 November 2011."},{"key":"e_1_2_7_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01306.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2012.01610.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2012.01610.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:09:12Z","timestamp":1761890952000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2012.01610.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1463-1326.2012.01610.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01610.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]}}}